110 results on '"Janini, Luiz"'
Search Results
102. Neutralizing antibody response after immunization with a COVID-19 bivalent vaccine: Insights to the future.
- Author
-
Souza MS, Farias JP, Andreata-Santos R, Silva MP, Brito RDDS, Duarte Barbosa da Silva M, Peter CM, Cirilo MVF, Luiz WB, Birbrair A, Vidal PO, de Castro-Amarante MF, Candido ED, Munhoz AS, de Mello Malta F, Dorlass EG, Machado RRG, Pinho JRR, Oliveira DBL, Durigon EL, Maricato JT, Braconi CT, Ferreira LCS, Janini LMR, and Amorim JH
- Subjects
- Humans, SARS-CoV-2 genetics, Vaccination, Immunization, Secondary, Antibodies, Neutralizing, Epitopes genetics, Vaccines, Combined, COVID-19 Vaccines, COVID-19 prevention & control
- Abstract
The raising of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants led to the use of COVID-19 bivalent vaccines, which include antigens of the wild-type (WT) virus, and of the Omicron strain. In this study, we aimed to evaluate the impact of bivalent vaccination on the neutralizing antibody (NAb) response. We enrolled 93 volunteers who had received three or four doses of monovalent vaccines based on the original virus (n = 61), or a booster shot with the bivalent vaccine (n = 32). Serum samples collected from volunteers were subjected to neutralization assays using the WT SARS-CoV-2, and Omicron subvariants. In addition, immunoinformatics to quantify and localize highly conserved NAb epitopes were performed. As main result, we observed that the neutralization titers of samples from individuals vaccinated with the bivalent vaccine were higher for the original virus, in comparison to their capacity of neutralizing the Omicron variant and its subvariants. NAb that recognize epitopes mostly conserved in the WT SARS-CoV-2 were boosted, while those that recognize epitopes mostly present in the Omicron variant, and subvariants were primed. These results indicate that formulation of future vaccines shall consider to target present viruses, and not viruses that no longer circulate., (© 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
103. Polymeric nanoparticles and nanomicelles of hydroxychloroquine co-loaded with azithromycin potentiate anti-SARS-CoV-2 effect.
- Author
-
de Barros AODS, Pinto SR, Dos Reis SRR, Ricci-Junior E, Alencar LMR, Bellei NCJ, Janini LRM, Maricato JT, Rosa DS, and Santos-Oliveira R
- Abstract
The outbreak of coronavirus (COVID-19) has put the world in an unprecedented scenario. To reestablish the world routine as promote the effective treatment of this disease, the world is looking for new (and old) drug that can efficiently kill the virus. In this study, we have developed two nanosystems: polymeric nanoparticles and nanomicelles-based on hydroxychloroquine and azithromycin. The nanosystem was fully characterized by AFM and DLS techniques. Also, the nanosystems were radiolabeled with
99m Tc and pulmonary applied (installation) in vivo to evaluate the biological behavior. The toxicity of both nanosystem were evaluated in primary cells (FGH). Finally, both nanosystems were evaluated in vitro against the SARS-CoV-2. The results demonstrated that the methodology used to produce the nanomicelles and the nanoparticle was efficient, the characterization showed a nanoparticle with a spherical shape and a medium size of 390 nm and a nanomicelle also with a spherical shape and a medium size of 602 nm. The nanomicelles were more efficient (~ 70%) against SARS-CoV-2 than the nanoparticles. The radiolabeling process with99m Tc was efficient (> 95%) in both nanosystems and the pulmonary application demonstrated to be a viable route for both nanosystems with a local retention time of approximately, 24 h. None of the nanosystems showed cytotoxic effect on FGH cells, even in high doses, corroborating the safety of both nanosystems. Thus, claiming the benefits of the nanotechnology, especially with regard the reduced adverse we believe that the use of nanosystems for COVID-19 treatment can be an optimized choice., Supplementary Information: The online version contains supplementary material available at 10.1007/s40097-022-00476-3., (© The Author(s), under exclusive licence to Islamic Azad University 2022.)- Published
- 2023
- Full Text
- View/download PDF
104. Plasma Metabolomics Biosignature According to HIV Stage of Infection, Pace of Disease Progression, Viremia Level and Immunological Response to Treatment.
- Author
-
Scarpellini B, Zanoni M, Sucupira MC, Truong HM, Janini LM, Segurado ID, and Diaz RS
- Abstract
Background: We evaluated plasma samples HIV-infected individuals with different phenotypic profile among five HIV-infected elite controllers and five rapid progressors after recent HIV infection and one year later and from 10 individuals subjected to antiretroviral therapy, five of whom were immunological non-responders (INR), before and after one year of antiretroviral treatment compared to 175 samples from HIV-negative patients. A targeted quantitative tandem mass spectrometry metabolomics approach was used in order to determine plasma metabolomics biosignature that may relate to HIV infection, pace of HIV disease progression, and immunological response to treatment., Results: Twenty-five unique metabolites were identified, including five metabolites that could distinguish rapid progressors and INRs at baseline. Severe deregulation in acylcarnitine and sphingomyelin metabolism compatible with mitochondrial deficiencies was observed. β-oxidation and sphingosine-1-phosphate-phosphatase-1 activity were down-regulated, whereas acyl-alkyl-containing phosphatidylcholines and alkylglyceronephosphate synthase levels were elevated in INRs. Evidence that elite controllers harbor an inborn error of metabolism (late-onset multiple acyl-coenzyme A dehydrogenase deficiency [MADD]) was detected., Conclusions: Blood-based markers from metabolomics show a very high accuracy of discriminating HIV infection between varieties of controls and have the ability to predict rapid disease progression or poor antiretroviral immunological response. These metabolites can be used as biomarkers of HIV natural evolution or treatment response and provide insight into the mechanisms of the disease., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2016
- Full Text
- View/download PDF
105. The detection of in vivo and in vitro HIV type 1 B/F profiles in Brazil using a real-time PCR assay for five HIV type 1 genomic regions.
- Author
-
Teixeira D, Munerato P, Komninakis SC, Fusuma EE, Janini LM, Sucupira MC, and Diaz RS
- Subjects
- Brazil epidemiology, Cell Line, Genome, Viral, Humans, Phylogeny, Polymerase Chain Reaction, RNA, Viral genetics, Sensitivity and Specificity, Sequence Analysis, RNA, HIV Infections epidemiology, HIV-1 genetics
- Abstract
We sought to determine the frequency and profile of HIV-1 BF recombinants in vitro and in vivo. Laboratory HIV-1 strains from subtypes B and F were cocultured and evaluated. Clinical samples from the city of Santos, Brazil, where the first HIV-1 B/F circulating recombinant forms (CRF) were described, were also assessed. Five real-time PCR assays were developed to equally amplify subtypes B and F, and subtype-specific probes were developed and optimized. To validate the PCR systems, clinical samples from Santos were sequenced and phylogenetically analyzed. The real-time PCR assays were performed on these samples and on the supernatant of an in vitro competition assay to assess emergent recombinant strains. Out of 157 clinical samples, 62.1% were defined as subtype B, 3.0% were subtype F, 16.7% presented the CRF28_BF profile, and 13.6% of the samples presented the CRF29_BF profile. The specificity and sensitivity in the discrimination assay for this sample panel were 93% and 92%, respectively. The HIV that emerged from the coinfected cell culture closely resembled the CRF28_BF profile. The first-described CRFs are still fixed in this geographic region of Brazil, and the in vitro emerging strains detected by real-time PCR suggest that in addition to the shaping of recombinant strains by immune selection, viral structures may also play an important role in emerging CRFs.
- Published
- 2010
- Full Text
- View/download PDF
106. Intrahost and interhost variability of the HIV type 1 nef gene in Brazilian children.
- Author
-
Cavalieri E, Florido C, Leal E, Machado DM, Camargo M, Diaz RS, and Janini LM
- Subjects
- Adult, Amino Acid Sequence, Brazil epidemiology, Child, Child, Preschool, Gene Products, nef chemistry, Gene Products, nef genetics, Gene Products, nef metabolism, Genes, MHC Class I genetics, Genes, MHC Class I physiology, HIV Infections epidemiology, Humans, Infant, Infant, Newborn, Molecular Sequence Data, Mutation, Phylogeny, Recombination, Genetic, Sequence Alignment, Sequence Analysis, DNA, nef Gene Products, Human Immunodeficiency Virus, Genes, nef, Genetic Variation, HIV Infections virology, HIV-1 classification, HIV-1 genetics
- Abstract
Many aspects of HIV-1 pathogenesis are affected by Nef protein activity, and efforts have been made to study variation in the nef gene and how that variation relates to disease outcome. We studied the genetic diversity of the nef gene in distinct clones obtained from the same patient (intrahost) and in sequences obtained from different hosts (interhost). The set of sequences analyzed was obtained from HIV-1-infected Brazilian children and contained 112 clones from 25 children (intrahost samples), as well as 55 sequences from epidemiologically unlinked children (interhost samples). We found extensive site polymorphisms and amino acid length variations, mainly in the amino terminal region of the nef gene, between the myristoylation motif (MGxxxS) and the MHC-1 downregulation motif (Rxx). Analysis of the sequences deposited in the Los Alamos HIV sequences database ( www.hiv.lanl.gov ) indicated that the most frequent motif at the MHC-1 downregulation site in the subtype B strain is R(86%)A(64%)E(82%) (n = 1040) and R(78%)T(74%)E(56%) in the subtype C strain (n = 549). Conversely, the Brazilian subtype B isolates presented the motif R(81%)T(62%)E(67%) at this site (n = 64). A detailed analysis of selective pressures identified a concentration of codons under strong positive selection in the amino terminal region of the nef gene. We also determined that different sites are under positive selection in the subtype B and subtype C viruses. The amino acid composition in the MHC-1 downregulation motif of the nef gene in our sequences may indicate a distinct adaptive pattern of HIV-1 subtype B to the Brazilian host population.
- Published
- 2009
- Full Text
- View/download PDF
107. Profiling resistance-related mutations in the protease region of the pol gene: single genome sequencing of HIV in plasma and peripheral blood mononuclear cells.
- Author
-
Guimarães AP, Sa-Filho DJ, Sucupira MC, Janini LM, and Diaz RS
- Subjects
- Amino Acid Sequence, Drug Resistance, Viral genetics, Humans, Molecular Sequence Data, Mutation, Proviruses genetics, Sequence Alignment, Treatment Failure, Virion genetics, HIV genetics, HIV Infections drug therapy, HIV Infections virology, HIV Protease genetics, HIV Protease Inhibitors pharmacology, HIV Protease Inhibitors therapeutic use, Indinavir pharmacology, Indinavir therapeutic use, Leukocytes, Mononuclear virology, Plasma virology
- Abstract
Genotypic resistance is currently assessed through direct sequencing, which cannot detect resistant strains below 20%. We compared the genotypic resistance profile of virions and proviruses using population-based analysis and single genome sequencing of the protease region of the pol gene in samples collected from five individuals in whom indinavir monotherapy resulted in treatment failure. Single genome sequencing showed that not all strains present the same resistance mutations, which can be dispersed across different HIV genomes. The resistance profile found in plasma was very similar to that found in peripheral blood mononuclear cells (PBMCs), confirming the utility of assessing proviral DNA as for a means of determining antiretroviral resistance.
- Published
- 2008
- Full Text
- View/download PDF
108. Identification of two HIV type 1 circulating recombinant forms in Brazil.
- Author
-
De Sá Filho DJ, Sucupira MC, Caseiro MM, Sabino EC, Diaz RS, and Janini LM
- Subjects
- Adult, Brazil epidemiology, Gene Products, gag genetics, Gene Products, gag physiology, HIV Infections epidemiology, HIV-1 isolation & purification, Humans, Male, Molecular Epidemiology, Phylogeny, Genetic Variation, HIV Infections virology, HIV-1 genetics, Recombination, Genetic
- Abstract
Recombination is an important way to generate genetic diversity. Accumulation of HIV-1 full-length genomes in databases demonstrated that recombination is pervasive in viral strains collected globally. Recombinant forms achieving epidemiological relevance are termed circulating recombinant forms (CRFs). CRF12_BF was up to now the only CRF described in South America. The objective was to identify the first CRF in Brazil conducting full genome analysis of samples sharing the same partial genome recombinant structure. Ten samples obtained from individuals residing in Santos, Brazil, sharing the same recombination pattern based on partial genome sequence data, were selected from a larger group to undergo full length genome analysis. Near full length genomes were assembled from overlapping fragments. Mosaic genomes were evaluated by Bootscan, alignment inspection, and phylogenetic analysis using neighbor joining and maximum likelihood. Full genomes were also analyzed by split decomposition. We were able to identify five mosaic genomes. Two of these structures were represented by at least three samples derived from epidemiologically unlinked individuals. These structures were named CRF28_BF and CRF29_BF and are the second and third CRFs composed exclusively by subtypes B and F as well as the second and third CRFs encountered in South America. Other recombinant forms studied here resembled CRF28_BF and CRF29_BF. Our results suggest that a diverse population of related recombinants, including CRFs may play an important part in the Brazilian and South American epidemic.
- Published
- 2006
- Full Text
- View/download PDF
109. Duplication of peri-kappaB and NF-kappab sites of the first human immunodeficiency virus type 2 (HIV-2) transmission in Brazil.
- Author
-
Fusuma EE, Caruso SC, Lopez DF, Costa LJ, Janini LM, De Mendonça JS, Kallas EG, and Diaz RS
- Subjects
- Base Sequence, Brazil, CD4 Lymphocyte Count, Female, HIV Infections complications, HIV Long Terminal Repeat genetics, HIV-2 isolation & purification, Humans, Middle Aged, Molecular Sequence Data, Phylogeny, Pneumonia, Pneumocystis complications, Sequence Analysis, DNA, HIV Enhancer genetics, HIV Infections transmission, HIV Infections virology, HIV-2 genetics
- Abstract
After the identification of HIV-2 in 1986, most of the cases reported have been concentrated in West Africa. We identified a case of HIV-2 infection in São Paulo, Brazil of a 45-year-old female who presented with Pneumocystis carinii pneumonia, with a CD4 count of 22 cells/ml. DNA samples from this patient were subjected to end-point PCR amplification of the LTR region. Clones were sequenced and subjected to phylogenetic analyses. All clones were subtype A related, and four presented an insertion, corresponding to an extra NF-kappaB site. This is the first confirmed case report of an HIV-2-infected subject identified in Brazil whose transmission occurred within the country. Furthermore, the NF-kappaB duplication would potentially be associated with an increase in viral cytopathogenicity. This raises concern for the need for permanent monitoring of the spread of HIV-2 in different areas of the world, even considering its lower rate of transmission and pathogenicity when compared to HIV-1.
- Published
- 2005
- Full Text
- View/download PDF
110. Analysis of full-length human immunodeficiency virus type 1 genome reveals a variable spectrum of subtypes B and f recombinants in São Paulo, Brazil.
- Author
-
Sa Filho DJ, Sanabani S, Diaz RS, Munerato P, Brunstein A, Fusuma E, Sabino EC, and Janini LM
- Subjects
- Brazil, Genes, pol, Phylogeny, Genome, Viral, HIV-1 classification, HIV-1 genetics, Recombination, Genetic
- Abstract
Recombination is one of the major mechanisms contributing to human immunodeficiency virus type 1 (HIV-1) variability. Analysis of pol gene sequences of 215 HIV-1 samples from São Paulo, Brazil classified 189 sequences as subtype B (87.9%), 8 sequences as subtype F (3.7%), and 18 sequences (8.4%) as B/F recombinants. After the analysis of the pol gene, a subset of six recombinant samples composed of sequences with a related recombinant pol structure was selected for full-length genome analysis to identify a possible circulating recombinant form. According to full-length genome analysis, recombination was higher in gag, protease, reverse transcriptase, integrase, and vif. Identification of many distinct recombinant forms and the absence of an identifiable HIV-1 circulating recombinant form suggest that a high frequency of dual infections between HIV-1 subtypes B and F is occurring in São Paulo, Brazil.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.